JP2011510327A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510327A5
JP2011510327A5 JP2010544349A JP2010544349A JP2011510327A5 JP 2011510327 A5 JP2011510327 A5 JP 2011510327A5 JP 2010544349 A JP2010544349 A JP 2010544349A JP 2010544349 A JP2010544349 A JP 2010544349A JP 2011510327 A5 JP2011510327 A5 JP 2011510327A5
Authority
JP
Japan
Prior art keywords
predetermined value
subject
gelsolin
plasma
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010544349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510327A (ja
JP5778425B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000452 external-priority patent/WO2009094194A2/en
Publication of JP2011510327A publication Critical patent/JP2011510327A/ja
Publication of JP2011510327A5 publication Critical patent/JP2011510327A5/ja
Application granted granted Critical
Publication of JP5778425B2 publication Critical patent/JP5778425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010544349A 2008-01-25 2009-01-23 腎不全におけるゲルソリンの診断的および治療的使用 Active JP5778425B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2378908P 2008-01-25 2008-01-25
US61/023,789 2008-01-25
PCT/US2009/000452 WO2009094194A2 (en) 2008-01-25 2009-01-23 Diagnostic and therapeutic uses of gelsolin in renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015005994A Division JP6042915B2 (ja) 2008-01-25 2015-01-15 腎不全におけるゲルソリンの診断的および治療的使用

Publications (3)

Publication Number Publication Date
JP2011510327A JP2011510327A (ja) 2011-03-31
JP2011510327A5 true JP2011510327A5 (https=) 2013-08-29
JP5778425B2 JP5778425B2 (ja) 2015-09-16

Family

ID=40901583

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010544349A Active JP5778425B2 (ja) 2008-01-25 2009-01-23 腎不全におけるゲルソリンの診断的および治療的使用
JP2015005994A Active JP6042915B2 (ja) 2008-01-25 2015-01-15 腎不全におけるゲルソリンの診断的および治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015005994A Active JP6042915B2 (ja) 2008-01-25 2015-01-15 腎不全におけるゲルソリンの診断的および治療的使用

Country Status (10)

Country Link
US (2) US9575072B2 (https=)
EP (2) EP2250280B1 (https=)
JP (2) JP5778425B2 (https=)
CA (2) CA2749985C (https=)
DK (2) DK2250280T3 (https=)
ES (2) ES2634263T3 (https=)
HU (1) HUE032875T2 (https=)
PL (2) PL2250280T3 (https=)
PT (2) PT2708603T (https=)
WO (1) WO2009094194A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1694342T3 (da) * 2003-11-12 2021-02-08 Univ Pennsylvania Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
EP1755661B1 (en) 2004-05-12 2014-03-12 The Brigham And Women's Hospital, Inc. Gelsolin for use in treating infections
HUE035980T2 (hu) * 2006-03-15 2018-06-28 Brigham & Womens Hospital Inc Gelzolin alkalmazása szklerózis multiplex kezelésére és neurológiai betegségek diagnosztizálására
ES2641879T3 (es) 2006-03-15 2017-11-14 The Brigham And Women's Hospital, Inc. Uso de gelsolina para diagnosticar y tratar enfermedades inflamatorias
EP2153234A2 (en) * 2007-05-11 2010-02-17 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
WO2010025128A1 (en) * 2008-08-25 2010-03-04 Critical Biologics Corporation Methods for reducing sample size of clinical trials
ES2356217B1 (es) * 2009-08-04 2012-02-13 Universidad De Salamanca Método para la detección de daño renal.
TW201601741A (zh) * 2013-09-09 2016-01-16 品特生物療法有限公司 用於治療esrd病患之pew的肌肉生長抑制素拮抗劑
CN104004780A (zh) * 2014-06-17 2014-08-27 南京大学 一种人胞质凝溶胶蛋白的表达纯化方法
WO2016033187A1 (en) * 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
JP6947449B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
CN114599386A (zh) * 2019-06-21 2022-06-07 生物保护医疗公司 用于治疗感染的组合物和协同方法
JP2023524604A (ja) * 2020-05-04 2023-06-12 バイオイージス・セラピューティクス・インコーポレーテッド 虚弱を処置するためのゲルソリンを含む組成物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) * 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
DK0526544T3 (da) * 1990-04-11 1999-06-21 Brigham & Womens Hospital Terapeutiske anvendelser af actinbindende forbindelser
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
AU8086191A (en) 1990-05-04 1991-11-27 Biogen, Inc. Multimeric gelsolin fusion constructs
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5360350A (en) * 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
CA2141600A1 (en) 1992-08-03 1994-02-17 Richard U. Margolis Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
WO1994008049A1 (en) 1992-10-01 1994-04-14 The General Hospital Corporation Functional assay for tumor suppressor genes
US5830436A (en) 1993-03-30 1998-11-03 Duke University Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) * 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5563153A (en) 1995-02-22 1996-10-08 University Of Kansas Medical Center Sterile topical anesthetic gel
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US5804427A (en) * 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5925529A (en) * 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
WO1998004589A2 (en) 1996-07-30 1998-02-05 Biogen, Inc. Production of recombinant plasma gelsolin containing a disulfide bond
PT941108E (pt) * 1996-12-04 2003-01-31 Renovo Ltd Cicatrizacao de feridas e tratamento da fibrose
ES2239801T3 (es) * 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
MXPA02003420A (es) 1999-10-06 2002-08-20 Basf Ag Inhibidores de la via de senalizacion de endotelina y antagonistas de los receptores de alfav°3 integrina para el tratamiento en combinacion.
AU2002225219A1 (en) 2001-01-26 2002-08-06 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
CA2439852A1 (en) 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
HRP20040102A2 (en) 2001-07-09 2004-10-31 Combinatorx Combinations for the treatment of inflammatory disorders
EP1432728A4 (en) 2001-08-30 2007-10-24 Praecis Pharm Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
AU2003296875B2 (en) 2002-02-06 2008-01-24 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
US20080051348A1 (en) 2002-02-06 2008-02-28 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2003088811A2 (en) 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
WO2004082617A2 (en) 2003-03-14 2004-09-30 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing rheumatoid arthritis
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
DK1694342T3 (da) 2003-11-12 2021-02-08 Univ Pennsylvania Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis
EP1706136A4 (en) 2003-12-22 2009-09-16 Regenerx Biopharmaceuticals PROCESS FOR TREATING OR PREVENTING BIOLOGICAL OR IMMUNE RESPONSES TO A REACTIVE CHEMICAL OR BIOLOGICAL OR TOXIC SUBSTANCE
CA2552425C (en) 2004-02-27 2018-02-06 F. Hoffmann-La Roche Ag Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
EP1755661B1 (en) * 2004-05-12 2014-03-12 The Brigham And Women's Hospital, Inc. Gelsolin for use in treating infections
AU2005249566B2 (en) 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
DK1929297T3 (da) 2005-09-29 2013-03-04 Caprion Proteomics Usa Llc Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse heraf
HUE035980T2 (hu) * 2006-03-15 2018-06-28 Brigham & Womens Hospital Inc Gelzolin alkalmazása szklerózis multiplex kezelésére és neurológiai betegségek diagnosztizálására
ES2641879T3 (es) 2006-03-15 2017-11-14 The Brigham And Women's Hospital, Inc. Uso de gelsolina para diagnosticar y tratar enfermedades inflamatorias
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
KR101568323B1 (ko) 2014-01-08 2015-11-12 한국원자력의학원 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease

Similar Documents

Publication Publication Date Title
JP2011510327A5 (https=)
Samsudin et al. Clinical utility and measurement of procalcitonin
Kedzierski et al. Suppressor of cytokine signaling (SOCS) 5 ameliorates influenza infection via inhibition of EGFR signaling
Gao et al. Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis
Harris et al. Double-stranded RNA induces molecular and inflammatory signatures that are directly relevant to COPD
Harris et al. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response
Hoffman et al. Protein disulfide isomerase–endoplasmic reticulum resident protein 57 regulates allergen-induced airways inflammation, fibrosis, and hyperresponsiveness
WO2012041334A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
Belknap et al. The challenges of interstitial cystitis: current status and future prospects
Coudroy et al. Modulation by polymyxin-B hemoperfusion of inflammatory response related to severe peritonitis
WO2013143548A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
Shaker et al. Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic nephropathy patients
Song et al. C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury
Stefaniak et al. Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation
Takase et al. Evaluation of risk for incident hypertension using glomerular filtration rate in the normotensive general population
RU2016147122A (ru) Применение серелаксина для снижения gdf-15
JP2017519008A5 (https=)
Zhang et al. Interleukin-33 promotes the inflammatory reaction in chronic rhinosinusitis with nasal polyps by NF-κB signaling pathway.
Parenica et al. Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality
WO2019023181A1 (en) METHODS OF TREATING INFLUENZA-RELATED VIRAL PNEUMONIA
Maiwall et al. Acute kidney injury (AKI) in patients with Acute on Chronic Liver failure (ACLF) is different from patients with cirrhosis: 128
KR100953821B1 (ko) 비타민 d 결합 단백질을 이용한 천식 진단 마커 및 천식치료제
Uysal Chronic Obstructive Pulmonary Disease and Metabolic Syndrome
Furusyo et al. High molecular weight form of adiponectin levels of Japanese patients with chronic hepatitis C virus infection
Pourmand et al. Urinary Tamm-Horsfall protein and citrate: a case-control study of inhibitors and promoters of calcium stone formation